Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Tratamiento oncológico del angiosarcoma cutáneo. Revisión de la literatura
Información de la revista
Vol. 16. Núm. 1.
Páginas 49-58 (Enero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 16. Núm. 1.
Páginas 49-58 (Enero 2012)
DOI: 10.1016/S0123-9015(12)70030-6
Acceso a texto completo
Tratamiento oncológico del angiosarcoma cutáneo. Revisión de la literatura
Oncologic Treatment of Cutaneous Angiosarcoma. Review of the Literature
Visitas
...
Javier A. Quintero1,2,
Autor para correspondencia
jaquinte2001@yahoo.com

Correspondencia: Departamento de Oncología Clínica, Instituto Nacional de Cancerología Av 1a N° 9-85, Bogotá, Colombia. Tel.:éfono: (571) 3341111 ext. 5439.
, Jesús O. Sánchez1, Néstor E. Llinás1, Isabel C. Durango1, Cristina Guarnizo3, Juan A. Rubiano1, Giovanna Rivas1, Fabio Grosso1, Javier Cuello1, Natalia Arango1,2
1 Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
2 Universidad del Bosque, Bogotá, D. C., Colombia
3 Subdirección de Investigaciones, Vigilancia Epidemiológica, Promoción y Prevención, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

El hemangiosarcoma cutáneo es una enfermedad maligna rara de origen vascular, y corresponde a menos del 1% de todas las malignidades y al 2% de todos los sarcomas de tejidos blandos. Su presentación usual es en el rostro y en la región del cuero cabelludo; al momento de diagnosticarse ya es una enfermedad avanzada. Afecta a menudo al anciano del género masculino y de raza blanca. El tratamiento oncológico se basa en la resección quirúrgica, la radioterapia y la quimioterapia, dado el alto riesgo tanto de recaída local como de diseminación hematológica con intención paliativa. Las tasas de control locorregional a 5 años son, aproximadamente, del 40% al 50%, las tasas de supervivencia libre de metástasis a distancia a 5 años están en el rango del 20% al 40%, y las tasas de supervivencia a 5 años se encuentran entre el 10% y el 30%.

Palabras clave:
hemangiosarcoma
neoplasias cutáneas
quimioterapia
radioterapia
Abstract

Cutaneous hemangiosarcoma is a rare malignant disease of vascular origin which accounts for less than 1% of all malignancies and 2% of all soft tissue sarcomas. It most frequently affects elderly white males, and is usually found on the face and scalp; at diagnosis it tends to be advanced. Oncologic treatment is based upon surgical resection, radiotherapy and chemotherapy due to the high risk of local relapse as well as to hematologic dissemination with palliative intention. Loco-regional control rates at 5 years range from 40% to 50%, metastasis-free survival rates at 5 years are from 20% to 40%, and survival rates at 5 years from 10% to 30%.

Key words:
Hemangiosarcoma
skin neoplasms
drug therapy
brachitherapy
El Texto completo está disponible en PDF
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
Referencias
[1.]
N. Mobini.
Cutaneous epithelioid angiosarcoma: a neoplasm with potential pitfalls in diagnosis.
J Cutan Pathol, 36 (2009), pp. 362-369
[2.]
C.A. Holden, M.F. Spittle, E.W. Jones.
Angiosarcoma of the face and scalp, prognosis and treatment.
Cancer, 59 (1987), pp. 1046-1057
[3.]
T.M. Pawlik, A.F. Paulino, C.J. McGinn, et al.
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.
Cancer, 98 (2003), pp. 1716-1726
[4.]
W.H. Morrison, R.M. Byers, A.S. Garden, et al.
Cutaneous angiosarcoma of the head and neck: a therapeutic dilemma.
Cancer, 76 (1995), pp. 319-327
[5.]
R. Sasaki, T. Soejima, K. Kishi, et al.
Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome.
Int J Radiat Oncol Biol Phys, 52 (2002), pp. 1032-1040
[6.]
E. Alessi, F. Sala, E. Berti.
Angiosarcomas in lymphedematous limbs.
Am J Dermatopathol, 8 (1986), pp. 371-378
[7.]
F.W. Stewart, N. Treves.
Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica.
CA Cancer J Clin, 31 (1981), pp. 284-299
[8.]
C. Marchal, B. Weber, B. de Lafontan, et al.
Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive cancer centers.
Int J Radiat Oncol Biol Phys, 44 (1999), pp. 113-119
[9.]
J. Yap, P.J. Chuba, R. Thomas, et al.
Sarcoma as a second malignancy after treatment for breast cancer.
Int J Radiat Oncol Biol Phys, 52 (2002), pp. 1231-1237
[10.]
M.G. Fury, C.R. Antonescu, K.J. Van Zee, et al.
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.
Cancer J, 11 (2005), pp. 241-247
[11.]
R.J. Mark, J.C. Poen, L.M. Tran, et al.
Angiosarcoma. A report of 67 patients and a review of the literature.
[12.]
J. Fayette, E. Martin, S. Piperno-Neumann, et al.
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.
Ann Oncol, 18 (2007), pp. 2030-2036
[13.]
W.M. Mendenhall, C.M. Mendenhall, J.W. Werning, et al.
Cutaneous angiosarcoma.
Am J Clin Oncol, 29 (2006), pp. 524-528
[14.]
N. Penel, J. Grosjean, Y.M. Robin, et al.
Frequency of certain established risk factors in soft tissue sarcomas In adult: a prospective descriptive study of 658 cases.
Sarcoma, 2008 (2008), pp. 459386
[15.]
M. Costache, A. Ene, O. Simionescu, et al.
Histopathological diagnosis of cutaneous vascular sarcomas.
Rom J Morphol Embryol, 51 (2010), pp. 105-109
[16.]
Y. Amo, M. Masuzawa, Y. Hamada, et al.
Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients.
Br J Dermatol, 150 (2004), pp. 160-161
[17.]
Y. Amo, M. Masuzawa, Y. Hamada, et al.
Observations on angiopoietin 2 in patients with angiosarcoma.
Br J Dermatol, 150 (2004), pp. 1028-1029
[18.]
D. Dim, V. Ravi, J. Tan, et al.
The actin-bundling motility protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma.
Proc Am Soc Clin Oncol, 25 (2007), pp. 10068
[19.]
E. Itakura, H. Yamamoto, Y. Oda, et al.
Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas.
J Surg Oncol, 97 (2008), pp. 74-81
[20.]
C. Zietz, U. Rumpler, M. Sturzl, et al.
Inverse relation of Fasligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.
Am J Pathol, 159 (2001), pp. 963-970
[21.]
T. Yamamoto, T. Umeda, K. Nishioka.
Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma.
Acta Derm Venereol, 80 (2000), pp. 443-445
[22.]
H. Isoda, M. Imai, S. Inagawa, et al.
Magnetic resonance imaging findings of angiosarcoma of the scalp.
J Comput Assist Tomogr, 29 (2005), pp. 858-862
[23.]
AJCC Cancer Staging Manual, 7th, pp. 291-298
[24.]
N. Naka, M. Ohsawa, Y. Tomita, et al.
Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases.
[25.]
J.A. Abraham, F.J. Hornicek, A.M. Kaufman, et al.
Treatment and outcome of 82 patients with angiosarcoma.
Ann Surg Oncol, 14 (2007), pp. 1953-1967
[26.]
P.G. Casali, L. Jost, S. Sleijfer, On behalf of the ESMO Guidelines Working Group, et al.
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol, 19 (2008), pp. 89-93
[27.]
C. Girard, W.C. Johnson, J.H. Graham.
Cutaneous angiosarcoma.
Cancer, 26 (1970), pp. 868-883
[28.]
E. Wilson-Jones.
Malignant angioendothelioma of the skin.
Br J Dermatol, 76 (1964), pp. 21-39
[29.]
S.L. DeMartelaere, D. Roberts, M. Burgess, et al.
Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement.
Head Neck, 30 (2008), pp. 639-646
[30.]
E.S. Casper, R.J. Waltzman, G.K. Schwartz, et al.
Phase II trial of paclitaxel in patients with soft-tissue sarcoma.
Cancer Invest, 16 (1998), pp. 442-446
[31.]
F. Fata, E. O’Reilly, D. Ilson, et al.
Placitaxel in the treatment of patients with angiosarcoma of the scalp or face.
Cancer, 86 (1999), pp. 2034-2037
[32.]
A. Verleysen, K. Dewolf, M.L. Geerts, et al.
Angiosarcoma of the face and scalp.
Eur J Dermatol, 10 (2000), pp. 403-404
[33.]
T. Nagano, Y. Yamada, T. Ikeda, et al.
Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients.
Cancer, 110 (2007), pp. 648-651
[34.]
N. Penel, B.N. Bui, J.O. Bay, et al.
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
J Clin Oncol, 26 (2008), pp. 5269-5274
[35.]
K.M. Skubitz, P.A. Haddad.
Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
Cancer, 104 (2005), pp. 361-366
[36.]
R.J. Young, N.J. Brown, M.W. Reed, et al.
Angiosarcoma Lancet Oncol, 11 (2010), pp. 983-991
[37.]
M. Agulnik, S.H. Okuno, M. Von Mehren, et al.
An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma.
J Clin Oncol, 27 (2009), pp. 10522
[38.]
R.G. Maki, D.R. D’Adamo, M.L. Keohan, et al.
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
J Clin Oncol, 27 (2009), pp. 3133-3140
[39.]
C.W. Ryan, M. von Mehren, J.C. Rankin, et al.
Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505.
Proc Am Soc Clin Oncol, 26 (2008), pp. 10532
[40.]
S. George, P. Merriam, R.G. Maki, et al.
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
J Clin Oncol, 27 (2009), pp. 3154-3160
[41.]
R. Chugh, J.K. Wathen, R.G. Maki, et al.
Phase II multicenter trial of Imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model.
J Clin Oncol, 27 (2009), pp. 3148-3153
[42.]
B.T. Burns, S.A. Blakey, W.B. Harris.
Complete response of metastatic angiosarcoma to liposomal doxorubicin and interferon-2a.
Proc Am Soc Clin Oncol, 21 (2002), pp. 2939
[43.]
T. Ohguri, H. Imada, S. Nomoto, et al.
Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy.
Int J Radiat Oncol Biol Phys, 61 (2005), pp. 1446-1453
Copyright © 2012. Instituto Nacional de Cancerología
Opciones de artículo
Herramientas